Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2022 17:43 ET | Source: Fluidigm Corporation

Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
February 17, 2022 08:30 ET | Source: Fluidigm Corporation

Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
February 14, 2022 06:10 ET | Source: Fluidigm Corporation

Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy...
January 24, 2022 08:30 ET | Source: Fluidigm Corporation

Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.

Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm, Former CTO of Danaher...
January 11, 2022 08:00 ET | Source: Fluidigm Corporation

Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021

Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth...
December 07, 2021 08:30 ET | Source: Fluidigm Corporation

Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant of COVID-19

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
November 16, 2021 08:30 ET | Source: Fluidigm Corporation

Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
November 11, 2021 08:30 ET | Source: Fluidigm Corporation

Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost

Streamlines Operations to Reduce Hands-On Time, Accelerate Results Broad Menu of Applications with Automated Workflow Providing Sample-to-Answer Solutions on a Single Platform SOUTH SAN...
November 08, 2021 16:02 ET | Source: Fluidigm Corporation

Fluidigm Announces Third Quarter 2021 Financial Results

Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology...
November 08, 2021 08:30 ET | Source: Fluidigm Corporation

Imaging Mass Cytometry Utilized to Seek Molecular Links between African Ancestry and Aggressive Forms of Breast and Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right